Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Abstract Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application in repressing cancer progression. Traditional cancer vaccines containing a single or a few discrete tumor epitopes have failed...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Exploration |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/EXP.20230171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846116366718861312 |
|---|---|
| author | Muyang Yang Jie Zhou Liseng Lu Deqiang Deng Jing Huang Zijian Tang Xiujuan Shi Pui‐Chi Lo Jonathan F. Lovell Yongfa Zheng Honglin Jin |
| author_facet | Muyang Yang Jie Zhou Liseng Lu Deqiang Deng Jing Huang Zijian Tang Xiujuan Shi Pui‐Chi Lo Jonathan F. Lovell Yongfa Zheng Honglin Jin |
| author_sort | Muyang Yang |
| collection | DOAJ |
| description | Abstract Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application in repressing cancer progression. Traditional cancer vaccines containing a single or a few discrete tumor epitopes have failed in the clinic, possibly due to challenges in epitope selection, target downregulation, cancer cell heterogeneity, tumor microenvironment immunosuppression, or a lack of vaccine immunogenicity. Whole cancer cell or cancer membrane vaccines, which provide a rich source of antigens, are emerging as viable alternatives. Autologous and allogenic cellular cancer vaccines have been evaluated as clinical treatments. Tumor cell membranes (TCMs) are an intriguing antigen source, as they provide membrane‐accessible targets and, at the same time, serve as integrated carriers of vaccine adjuvants and other therapeutic agents. This review provides a summary of the properties and technologies for TCM cancer vaccines. Characteristics, categories, mechanisms, and preparation methods are discussed, as are the demonstrable additional benefits derived from combining TCM vaccines with chemotherapy, sonodynamic therapy, phototherapy, and oncolytic viruses. Further research in chemistry, biomedicine, cancer immunology, and bioinformatics to address current drawbacks could facilitate the clinical adoption of TCM vaccines. |
| format | Article |
| id | doaj-art-0a5a65f20c9c4bbab5f8c56d5fd8568a |
| institution | Kabale University |
| issn | 2766-8509 2766-2098 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Exploration |
| spelling | doaj-art-0a5a65f20c9c4bbab5f8c56d5fd8568a2024-12-19T04:18:00ZengWileyExploration2766-85092766-20982024-12-0146n/an/a10.1002/EXP.20230171Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapyMuyang Yang0Jie Zhou1Liseng Lu2Deqiang Deng3Jing Huang4Zijian Tang5Xiujuan Shi6Pui‐Chi Lo7Jonathan F. Lovell8Yongfa Zheng9Honglin Jin10College of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaCollege of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan ChinaCollege of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan ChinaCollege of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan ChinaCollege of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan ChinaCollege of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan ChinaDepartment of Biomedical Sciences City University of Hong Kong Kowloon Hong Kong ChinaDepartment of Biomedical Engineering University at Buffalo State University of New York Buffalo New York USADepartment of Oncology Renmin Hospital of Wuhan University Wuhan ChinaCollege of Biomedicine and Health and College of Life Science and Technology Huazhong Agricultural University Wuhan ChinaAbstract Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application in repressing cancer progression. Traditional cancer vaccines containing a single or a few discrete tumor epitopes have failed in the clinic, possibly due to challenges in epitope selection, target downregulation, cancer cell heterogeneity, tumor microenvironment immunosuppression, or a lack of vaccine immunogenicity. Whole cancer cell or cancer membrane vaccines, which provide a rich source of antigens, are emerging as viable alternatives. Autologous and allogenic cellular cancer vaccines have been evaluated as clinical treatments. Tumor cell membranes (TCMs) are an intriguing antigen source, as they provide membrane‐accessible targets and, at the same time, serve as integrated carriers of vaccine adjuvants and other therapeutic agents. This review provides a summary of the properties and technologies for TCM cancer vaccines. Characteristics, categories, mechanisms, and preparation methods are discussed, as are the demonstrable additional benefits derived from combining TCM vaccines with chemotherapy, sonodynamic therapy, phototherapy, and oncolytic viruses. Further research in chemistry, biomedicine, cancer immunology, and bioinformatics to address current drawbacks could facilitate the clinical adoption of TCM vaccines.https://doi.org/10.1002/EXP.20230171cancer immunotherapycancer vaccinetumor cell membranetumor‐derived extracellular vesicles |
| spellingShingle | Muyang Yang Jie Zhou Liseng Lu Deqiang Deng Jing Huang Zijian Tang Xiujuan Shi Pui‐Chi Lo Jonathan F. Lovell Yongfa Zheng Honglin Jin Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy Exploration cancer immunotherapy cancer vaccine tumor cell membrane tumor‐derived extracellular vesicles |
| title | Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy |
| title_full | Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy |
| title_fullStr | Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy |
| title_full_unstemmed | Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy |
| title_short | Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy |
| title_sort | tumor cell membrane based vaccines a potential boost for cancer immunotherapy |
| topic | cancer immunotherapy cancer vaccine tumor cell membrane tumor‐derived extracellular vesicles |
| url | https://doi.org/10.1002/EXP.20230171 |
| work_keys_str_mv | AT muyangyang tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT jiezhou tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT lisenglu tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT deqiangdeng tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT jinghuang tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT zijiantang tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT xiujuanshi tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT puichilo tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT jonathanflovell tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT yongfazheng tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy AT honglinjin tumorcellmembranebasedvaccinesapotentialboostforcancerimmunotherapy |